ESGCT Congress 2025

October 7-10, 2025, Seville, Spain

Developing gene therapies demands specialized expertise. Discover how our deep understanding of viral vector manufacturing processes, coupled with our state-of-the-art CDMO facility and tailored testing capabilities can address your unique challenges.

Viral Vector Upstream Production Platforms

Need to develop your upstream process? Discover how our upstream platforms together with our experienced technology and regulatory teams, can help you optimize your viral vector process to maximize your titer, setting the stage for better downstream production and timelines. Visit our booth for a first-class experience and on-time arrival of your AAV pipeline with our AAViator™ Production Platform  

Viral Vector CDMO Services

Ready to partner with a CDMO to support your development, manufacturing, and fill/finish needs? Backed by 30+ years of viral vector development and manufacturing experience and a superior regulatory track record, we have supported 4 commercially approved cell & gene therapies from pre-IND through routine supply. Connect with our team of experts to discover how our end-to-end CDMO solutions can accelerate your therapeutic from preclinical through commercial production.

Contract Testing Services

Seeking an expert partner for gene therapy characterization and release testing? With 75+ years of scientific and regulatory expertise in biosafety testing, be sure to stop by and meet our team who are eager to discuss with you how our comprehensive testing solutions can meet your needs and support your project’s success.

HEAR FROM OUR EXPERTS

Thursday, October 9th

13:30-14:00

Luncheon Symposium
To 1000L and Beyond: Innovating Upstream AAV Manufacturing for the Next Wave of Gene Therapies
Presenter: Fletcher Malcom, Director of Strategy, Product and Business Development

DIVE INTO POSTER DATA WITH US

Wednesday, October 8th

14:00 to 15:30

• Characterization of AAV Residuals Using Next Generation Sequencing and Orthogonal Methods to help Optimize Product Safety, Anna Woodword, ID# P0155
• Optimizing Detergent use for AAV Recovery and Viral Inactivation in Gene Therapy Manufacturing, Clothilde Decarnin, ID# PO165
• Next-Generation Sequencing for AAV Characterization, Jessica Hilmoe, ID# P0243
• Increasing rAAV Productivity through Selection of a High Producing HEK293 Transient Cell Line and Addition of an Enhancer, Jessica Hilmoe, ID# P0245
• Serotype Independent AAV Capture using Cation Exchange Membranes Integrated with Enhanced Midstream Processing, Thibaut Deschamps ID# P0905 

Thursday, October 9th

14:00 to 15:30

• Efficient Development of Transient HEK293 AAV Production Methods using an Optimized Upstream Platform, Benjamin Ross-Johnsrud, ID# P0120
• AEX HPLC Method Development for Determination of Empty/Full Ratios of AAV Capsids, Jessica Hilmoe, ID# P0154
• AAV Process Intensification: Balancing Yield and Product Quality, Antoine Heron ID# PO166 
• HEK Small Scale Perfusion Process Development, Antoine Heron, ID #P0168 
• Enabling Gene Therapy Manufacturing with a Scalable, Cost-Effective, High-Performance AAV Platform, Jessica Hilmoe, ID# P0246
• Fast and Reliable PAT-Raman Model Establishment for Upstream Monitoring of AAV Production, Thibaut Deschamps ID# P0864